RAS and RAF Mutation Status in the Selection of Patients for Anti-Egfr Therapy

Anti-EGFR therapy in combination or not with chemotherapy is one of the mainstays of treatment for advanced colorectal cancer. KRAS exon 2 mutations have been validated as negative predictors of response, despite of it, an important percentage of patients do not benefit from anti-EGFR therapy. Factors like other RAS and BRAF mutations could contribute to primary resistance to cetuximab and panitumumab. Evidence surrounding RAS and BRAF status determination before anti-EGFR therapy administration is reviewed here.